Bengal Physician Journal

Register      Login

VOLUME 7 , ISSUE 2 ( May-August, 2020 ) > List of Articles

REVIEW ARTICLE

COVID-19: Reflections, So Far

Keywords : Atlanta, Centers for Disease Control and Prevention, COVID-19, Global economy, Lockdown, Middle East respiratory syndrome, Quarantine, Severe acute respiratory syndrome coronavirus type 2, Suicide, Swachh Bharat, World Health Organization

Citation Information : COVID-19: Reflections, So Far. Bengal Physician Journal 2020; 7 (2):39-42.

DOI: 10.5005/jp-journals-10070-7019

License: CC BY-NC 4.0

Published Online: 01-08-2020

Copyright Statement:  Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Never in the history of mankind has the global scientific and medical community been subjected to such a testing time as in the coronavirus-2019 (COVID-19) pandemic triggered off by the novel RNA severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) virus of 125 nm size. Despite the concerted efforts of the entire world, we do not seem to be making progress in being able to confidently recommend evidence-based pharmacological interventions in affected patients or advise governments on immunological interventions to avoid mass fatalities that are already in very significant numbers throughout the developed and the developing world including unfortunately in India. This has been a wake-up call for researchers, virologists, and immunologists to undertake more critical research into the deficiencies of our knowledge base that has been exposed by the current pandemic. The shift of recent research since the last HIV scare in the early 1980s has been toward noncommunicable diseases and drug development has also followed the same trend. There has been considerable progress on antibiotic resistance although antiviral therapies have not made progress in line with potential emergence of novel viruses as has been cruelly demonstrated in this current pandemic. The immunological responses that have been so varied to the current pathogen in individuals are again a matter of further research and understanding of human immunology and its complex response to cancers, autoimmune diseases, and external pathogens—further research is necessary here. The long-term impact of COVID-19 illness spectrum remains to be seen as clinicians and basic scientists put their heads together to evaluate the clinical profile of the illness spectrum from case records of recovered patients and those who succumbed and evidence-based treatment approaches need to be available instead of the best guess treatments that we are practicing presently to save lives. Immunologists, virologists, clinical trial experts, and pharmacologists are now tasked to develop evidence-based pharmacological therapies and efficient vaccines to rebuild the confidence of the population and governments globally who have always relied upon and respected healthcare stakeholders to protect global health. We live in uncertain times filled with anxiety and disruption of normal human lifestyle habits. Never has the tolerance, patience, and fortitude of the global village, we live in and of the economic fallouts arising been tested to the hilt as much as we have seen in these last six months. Hopefully, we should be able to see the light at the end of the “COVID-19” tunnel soon. Going forward, we hope we emerge as a stronger human civilization being able to collaborate, cooperate, and cohabit this beautiful planet and together we become masters of our destiny so that future generations will be grateful to us for having taken responsible decisions during times of crisis that threatened our civilization and brought all of us proverbially to our knees.


PDF Share
  1. Coronavirus. Wikipedia, the free encyclopaedia. Retrieved on July 26, 2020. Available from: https://en.wikipedia.org/w/index.php?title=Coronavirus&oldid=969499748
  2. Coronavirus disease 2019. Wikipedia, the free encyclopaedia. Retrieved on July 26, 2020. Available from: https://en.wikipedia.org/w/index.php?title=Coronavirus_disease_2019&oldid=969612857
  3. Adedeji WA. The treasure called antibiotics. Ann Ib Postgrad Med 2016;14(2):56–57. PMID: 28337088, PMCID: PMC5354621.
  4. Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2012;2(4):a007161. DOI: 10.1101/cshperspect.a007161.
  5. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109(7):309–318. DOI: 10.1179/2047773215Y.0000000030.
  6. Cowen LE. The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nat Rev Microbiol 2008;6(3):187–198. DOI: 10.1038/nrmicro1835.
  7. Chowell G, Nishiura H. Transmission dynamics and control of Ebola virus disease (EVD): a review. BMC Med 2014;12:196. DOI: 10.1186/s12916-014-0196-0.
  8. List of largest biomedical companies by revenue. Wikipedia, the free encyclopaedia. Retrieved on July 26, 2020. Available from: https://en.wikipedia.org/w/index.php?title=List_of_largest_biomedical_companies_by_revenue&oldid=966143403
  9. Ramadan N, Shaib H. Middle East respiratory syndrome coronavirus (MERS-CoV): a review. Germs. 2019;9(1):35–42. DOI: 10.18683/germs.2019.1155.
  10. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507–513. DOI: 10.1016/S0140-6736(20)30211-7.
  11. Yi ES, Cecchini MJ, Bois MC. Pathologists in pursuit of the COVID-19 culprit. Lancet Infect Dis 2020;20(10):1102–1103. DOI: 10.1016/ S1473-3099(20)30449-7.
  12. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. 2020;20(10):1135–1140. DOI: 10.1016/S1473-3099(20)30434-5.
  13. Chu DK, Akl EA, Duda S, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet 2020;395(10242):1973–1987. DOI: 10.1016/S0140-6736(20)31142-9.
  14. Herron JBT, Hay-David AGC, Gilliam AD, et al. Personal protective equipment and COVID 19 a risk to healthcare staff? Br J Oral Maxillofac Surg 2020;58(5):500–502. DOI: 10.1016/j.bjoms.2020.04.015.
  15. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic transmission, the Achilles’ heel of current strategies to control Covid-19. N Engl J Med 2020;382(22):2158-2160. DOI: 10.1056/NEJMe2009758.
  16. Omer SB, Malani P, del Rio C. The COVID-19 pandemic in the US: a clinical update. JAMA 2020;323(18):1767–1768. DOI: 10.1001/jama.2020.5788.
  17. Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: current state of the science. Immunity 2020;52(6):910–941. DOI: 10.1016/j.immuni.2020.05.002.
  18. Sohrabi C, Alsafi Z, O’Neill N, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19) [published correction appears in Int J Surg 2020 May;77:217]. Int J Surg 2020;76:71–76. DOI: 10.1016/j.ijsu.2020.02.034.
  19. Ghinai I, McPherson TD, Hunter JC, et al. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet 2020;395(10230):1137–1144. DOI: 10.1016/S0140-6736(20)30607-3.
  20. Tomar A, Gupta N. Prediction for the spread of COVID-19 in India and effectiveness of preventive measures. Sci Total Environ 2020;728:138762. DOI: 10.1016/j.scitotenv.2020.138762.
  21. Kumar SU, Kumar DT, Christopher BP, et al. The rise and impact of COVID-19 in India. Front Med 2020;7:250. DOI: 10.3389/fmed.2020.00250.
  22. Lippi G, Sanchis-Gomar F, Henry BM. COVID-19: unravelling the clinical progression of nature's virtually perfect biological weapon. Ann Transl Med 2020;8(11):693. DOI: 10.21037/atm-20-3989.
  23. UN News. “This is a time for facts, not fear,” says WHO chief as COVID-19 virus spreads. Retrieved on February 15, 2020 Health. Available from: https://news.un.org/en/story/2020/02/1057481
  24. Julian Borger in Washington (Apr 8, 2020 23.53 BST). Trump scapegoating of WHO obscures its key role in tackling pandemic. Available from: https://www.theguardian.com/world/2020/apr/08/world-health-organization-coronavirus-donald-trump
  25. Patnaik S, Pereira V, Temouri Y. Getting our act together for COVID-19 drug development. Issues in Science and Technology. Retrieved on May 21, 2020. Available from: https://issues.org/covid-19-drug-development-infectious-disease-partnerships/#.Xx3QNp8pgEc.link.
  26. Amin T, Malpani R. Covid-19 has exposed the limits of the pharmaceutical market model. Retrieved on May 19, 2020. Available from: https://www.statnews.com/2020/05/19/covid-19-exposed-limits-drug-development-model/
  27. WHO: 2019 novel Coronavirus global research and innovation forum: towards a research roadmap. Available from: https://www.who.int/blueprint/priority-diseases/key-action/Roadmap-version-FINAL-for-WEB.pdf?ua=1
  28. Gaffney A, Himmelstein DU, Woolhandler S. COVID-19 and US health financing: perils and possibilities. Int J Health Serv 2020;50(4):396–407. DOI: 10.1177/0020731420931431.
  29. Nicola M, Alsafi Z, Sohrabi C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): a review. Int J Surg 2020;78:185–193. DOI: 10.1016/j.ijsu.2020.04.018.
  30. McKee M, Stuckler D. If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future. Nat Med 2020;26:640–642. DOI: 10.1038/s41591-020-0863-y.
  31. Kakar A, Nundy S. COVID-19 in India. J R Soc Med 2020;113(6):232–233. DOI: 10.1177/0141076820927668.
  32. Varshney M, Parel JT, Raizada N, et al. Initial psychological impact of COVID-19 and its correlates in Indian Community: an online (FEEL-COVID) survey. PLoS One 2020;15(5):e0233874. DOI: 10.1371/journal.pone.0233874.
  33. Krishnakumar B, Rana S. COVID 19 in INDIA: strategies to combat from combination threat of life and livelihood. J Microbiol Immunol Inf 2020;53(3):389–391. DOI: 10.1016/j.jmii.2020.03.024.
  34. Bandyopadhyay S. Coronavirus disease 2019 (COVID-19): we shall overcome. Clean Technol Environ Policy 2020;22:545–546. DOI: 10.1007/s10098-020-01843-w.
  35. Li H, Liu SM, Yu XH, et al. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents 2020;55(5):105951. DOI: 10.1016/j.ijantimicag.2020.105951.
  36. Kucharski AJ, Russell TW, Diamond C, et al. Early dynamics of transmission and control of COVID-19: a mathematical modelling study. Lancet Inf Dis 2020;20(5):553–558. DOI: 10.1016/S1473-3099(20)30144-4.
  37. Patel R, Babady E, Theel ES, et al. Report from the American Society for Microbiology COVID-19 International Summit, 23 March 2020: value of diagnostic testing for SARS–CoV-2/COVID-19. mBio 2020;11(2):e00722-20. DOI: 10.1128/mBio.00722-20.
  38. Peeling RW, Wedderburn CJ, Garcia PJ, et al. Serology testing in the COVID-19 pandemic response. Lancet 2020;20:E245–E249. DOI: 10.1016/S1473-3099(20)30517-X.
  39. Khawaja MA. COVID-19 pandemic and the global humanity. 05.04.2020 – Pressenza New York. Available from: https://www.pressenza.com/2020/04/covid-19-pandemic-and-the-global-humanity/
  40. pavamāna abhyāroha (abhyāroha, lit. “ascending,” being a Upanishadic technical term for “prayer.” Pavamana Mantras the Bṛhadāraṇyaka Upaniṣad “From falsehood lead me to truth, from darkness lead me to the light, from death lead me to immortality.” These three statements are referred to as the three Pavamana Mantras. Some renderings add ॐ (oṃ) at the beginning and ॐ शान् तिः शान् तिः शान् तिः ॥ (oṃ śāntiḥ śāntiḥ śāntiḥ, “om peace peace peace”) as a fourth line. This is a stylistic addition that concludes a recitation; as such, it is often included with the verse itself though the Upanishad itself does not end the line that way.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.